Health-care companies slipped as vaccine makers remained under pressure. Shares of Novavax plunged by 8%, compounding losses in the wake of the vaccine developer's earnings report. Rival Moderna lost ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

With the clinical hold now lifted, Novavax plans to resume trial activities and begin enrolling participants for the planned phase 3 studies, the release said. The hold had been imposed Oct. 16 ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago. These figures are adjusted ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...

More doctors are looking out for the condition. But that’s not enough to explain the increase in the nation’s overall ...